Bio-Techne Stock: Drug Pricing Deal Boosts Optimism

Why Bio-Techne Stock Soared (Then Stumbled): A potential drug pricing deal sent Bio-Techne shares soaring over 5%, but don't get too excited. Despite Pfizer's move to lower drug prices, Bio-Techne's volatile year continues, with cautious outlooks and market unpredictability keeping investors on edge. Is this a turning point or just another bump in the road for the life sciences company? Hosted on Acast. See acast.com/privacy for more information.